Skip to content
Michael Smolinsky

Michael Smolinsky

Contributing Writer

Michael W. Smolinsky is the Chief Content Officer of Ethis, whose mission is to facilitate global innovation in eye care by providing strategic analysis, exceptional content across a wide range of media, and an extensive network of key ophthalmic and optometric opinion leaders to industry and academic partners around the world.

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma
part-two-three-novel-partnerships-11-30-16

Three Novel Partnerships in Ophthalmology (Part Two)

Two weeks ago, we began reviewing collaborations between ophthalmic start-ups and institutions or groups that traditionally haven’t been involved in developing medical technology, such as ...
Read More
Three Novel Partnerships in Ophthalmology - Eye On Innovation Article - OIS - Healthegy

Three Novel Partnerships in Ophthalmology

The past year has witnessed the formation of several collaborations between ophthalmic start-ups and institutions or groups that traditionally haven’t been involved in developing medical ...
Read More
Stem Cell Therapies for AMD Making Strides - Eye On Innovation Article - OIS

Stem Cell Therapies for AMD Making Strides

In 2013, the first clinical study of stem cells in ophthalmology set high hopes that companies may one day develop cell-based therapies for neovascular age-related ...
Read More
Outlook for Combination Therapies in Retinal Disease - Eye on Innovation

Outlook for Combination Therapies in Retinal Disease

When Regeneron Pharmaceuticals and Bayer announced their collaboration to develop and commercialize a combination therapy using Regeneron’s vascular endothelial growth factor (VEGF) trap aflibercept (Eylea) ...
Read More
What’s New With Three Sustained-Release Drug Platforms - Eye on Innovation

What’s New with Three Sustained-Release Drug Platforms

Most ophthalmic drugs are delivered by topical application or direct injection into the vitreous, and many are limited by difficulties in sustaining therapeutic drug levels ...
Read More
Looking Deep at Extended Depth-of-Focus IOLs

Looking Deep at Extended Depth-of-Focus IOLs

Multifocal IOLs, perhaps the best established solution to the problem of enabling post-cataract patients to see clearly at all distances, work by incorporating discrete refractive ...
Read More
Premium IOLs: Two Outliers with Mainstream Potential

Premium IOLs: Two Outliers with Mainstream Potential

A problem that plagues refractive cataract surgery is the difficulty of determining the IOL power that will achieve each patient’s refractive target. In the old ...
Read More
A Look at Premium IOLs

A Look at Premium IOLs

Can Accommodating IOLs Fuel Demand? For nearly two decades, “presbyopia-correcting” intraocular lenses (IOLs) have been available to post-cataract surgery patients, but for a variety of ...
Read More
Scroll To Top